(4-{6-[((3R)oxolan-3-yl)amino]-2-chloropurin-9-yl}(1R,2R,4R,5R)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl)methan-1-ol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (4-{6-[((3R)oxolan-3-yl)amino]-2-chloropurin-9-yl}(1R,2R,4R,5R)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl)methan-1-ol
• 英文别名: [(3aR,4R,6R,6aR)-4-[2-chloro-6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
• 化学式: C₁₇H₂₂ClN₅O₅
• 分子量: 411.845
• InChiKey: BWNQPHIHSOYPLB-NENBDWHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (4-{6-[((3R)oxolan-3-yl)amino]-2-chloropurin-9-yl}(1R,2R,4R,5R)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl)methan-1-ol 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 Methyl-carbamic acid (3aR,4R,6R,6aR)-6-{2-chloro-6-[(R)-(tetrahydro-furan-3-yl)amino]-purin-9-yl}-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester
  参考文献：
  名称：

  Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

  摘要：

  The SAR for the affinity to the A, adenosine receptor and relative intrinsic efficacy (IE, [S-35]-GTPgammaS binding) of a series of 5'-carbamate and 5'-thionocarbamate derivatives of tecadenoson is described. Based on this SAR, selected compounds were evaluated in guinea pig isolated hearts to determine whether they were partial or full agonists with respect to their negative dromotropism, an A(1) AdoR mediated effect. Progress towards obtaining a partial A(1) AdoR agonist to potentially control ventricular rate during atrial fibrillation has been made with the discovery of several potent partial A(1) AdoR agonists (compounds 13, 14, and 17). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.094
• 作为产物：
  描述：

  (2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-(2,6-dichloro-9H-purin-9-yl)tetrahydro-3-furanyl acetate 在 camphor-10-sulfonic acid 、 氨 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 丙酮 为溶剂， 生成 (4-{6-[((3R)oxolan-3-yl)amino]-2-chloropurin-9-yl}(1R,2R,4R,5R)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl)methan-1-ol
  参考文献：
  名称：

  选择性A 1腺苷受体激动剂的基于结构的设计，合成和体内抗伤害作用

  摘要：

  我们以前的工作发现，在腺苷衍生物中结合适当的5'-和N 6-取代可导致高度选择性的人A 1腺苷受体（hA 1 AR）激动剂或高效的双重hA 1 AR激动剂和hA 3 AR拮抗剂。为了探索新颖的双腺苷受体配体，合成了一系列N 6-取代的5'-吡唑基-腺苷和2-氯-腺苷衍生物，并在所有AR中体外测定。所述Ñ 6 - （±） -内型-norbornyl衍生物12是最有效的和选择性A处1AR在福尔马林试验中可作为镇痛药有效，但5'-吡唑基系列化合物均未在hA 1和hA 3 AR处表现出双重行为。分子建模研究合理化了一系列新的A 1 AR激动剂的结构-活性关系和选择性。有趣的是，假设了N 6-四氢呋喃基衍生物14的意外的反向结合模式，以解释其对A 1 AR的低亲和力。

  DOI：

  10.1021/acs.jmedchem.7b01399

文献信息

• Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias
  申请人：——

  公开号：US20010008883A1

  公开（公告）日：2001-07-19

  The present invention provides a method for identifying parital adenosine A1 receptor agonists that are useful in the treatment of arrhythmias. Partial adenosine A1 receptor agonists and methods for using partial adenosine A1 receptor agonists to treat arrhythmias in mammals.

  本发明提供了一种用于识别对治疗心律失常有用的部分腺苷A1受体激动剂的方法。部分腺苷A1受体激动剂以及使用部分腺苷A1受体激动剂治疗哺乳动物心律失常的方法。
• Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A₁ Adenosine Receptor Agonists
  作者：Riccardo Petrelli、Mirko Scortichini、Carmela Belardo、Serena Boccella、Livio Luongo、Fabio Capone、Sonja Kachler、Patrizia Vita、Fabio Del Bello、Sabatino Maione、Antonio Lavecchia、Karl-Norbert Klotz、Loredana Cappellacci

  DOI：10.1021/acs.jmedchem.7b01399

  日期：2018.1.11

  N6-substitution in adenosine derivatives leads to the highly selective human A1 adenosine receptor (hA1AR) agonists or highly potent dual hA1AR agonists and hA3AR antagonists. In order to explore novel dual adenosine receptor ligands, a series of N6-substituted-5′-pyrazolyl-adenosine and 2-chloro-adenosine derivatives were synthesized and assayed in vitro at all ARs. The N6-(±)-endo-norbornyl derivative 12 was

  我们以前的工作发现，在腺苷衍生物中结合适当的5'-和N 6-取代可导致高度选择性的人A 1腺苷受体（hA 1 AR）激动剂或高效的双重hA 1 AR激动剂和hA 3 AR拮抗剂。为了探索新颖的双腺苷受体配体，合成了一系列N 6-取代的5'-吡唑基-腺苷和2-氯-腺苷衍生物，并在所有AR中体外测定。所述Ñ 6 - （±） -内型-norbornyl衍生物12是最有效的和选择性A处1AR在福尔马林试验中可作为镇痛药有效，但5'-吡唑基系列化合物均未在hA 1和hA 3 AR处表现出双重行为。分子建模研究合理化了一系列新的A 1 AR激动剂的结构-活性关系和选择性。有趣的是，假设了N 6-四氢呋喃基衍生物14的意外的反向结合模式，以解释其对A 1 AR的低亲和力。
• US6576620B2
  申请人：——

  公开号：US6576620B2

  公开（公告）日：2003-06-10
• Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors
  作者：Ehesan U. Sharif、Jaroslaw Kalisiak、Kenneth V. Lawson、Dillon H. Miles、Eric Newcomb、Erick A. Lindsey、Brandon R. Rosen、Laurent P. P. Debien、Ada Chen、Xiaoning Zhao、Stephen W. Young、Nigel P. Walker、Norbert Sträter、Emma R. Scaletti、Lixia Jin、Guifen Xu、Manmohan R. Leleti、Jay P. Powers

  DOI：10.1021/acs.jmedchem.0c01835

  日期：2021.1.14

  mechanism of adenosine generation. We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design. Key binding interactions of the known inhibitor adenosine-5′-(α,β-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs. The structure–activity relationship study guided by this structure-based design led to the discovery

  实体瘤通常与高水平的细胞外ATP相关。外源核酸酶催化ATP顺序水解为腺苷，通过腺苷受体（A 2a和A 2b）有效抑制T细胞和NK细胞功能）。胞外核苷酸酶CD73催化AMP向腺苷的转化。因此，在肿瘤微环境中增加的CD73酶活性是逃避肿瘤免疫的潜在机制，并且与临床预后不良有关。预期通过抑制腺苷生成的这一主要机制，可以抑制CD73来恢复免疫功能。我们已经通过基于结构的设计开发了一系列有效的和选择性的亚甲基膦酸CD73抑制剂。已知抑制剂腺苷5'-（α，β-亚甲基）二磷酸（AMPCP）与hCD73的关键结合相互作用为我们的早期设计奠定了基础。在这种基于结构的设计指导下进行的结构-活动关系研究导致了4a的发现，对CD73表现出优异的效力，对相关的外切核苷酸酶表现出出色的选择性，并具有良好的药代动力学特征。
• Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)
  作者：Venkata P Palle、Vaibhav Varkhedkar、Prabha Ibrahim、Hiba Ahmed、Zhihe Li、Zhenhai Gao、Mark Ozeck、Yuzhi Wu、Dewan Zeng、Lin Wu、Kwan Leung、Nancy Chu、Jeff A Zablocki

  DOI：10.1016/j.bmcl.2003.09.094

  日期：2004.1

  The SAR for the affinity to the A, adenosine receptor and relative intrinsic efficacy (IE, [S-35]-GTPgammaS binding) of a series of 5'-carbamate and 5'-thionocarbamate derivatives of tecadenoson is described. Based on this SAR, selected compounds were evaluated in guinea pig isolated hearts to determine whether they were partial or full agonists with respect to their negative dromotropism, an A(1) AdoR mediated effect. Progress towards obtaining a partial A(1) AdoR agonist to potentially control ventricular rate during atrial fibrillation has been made with the discovery of several potent partial A(1) AdoR agonists (compounds 13, 14, and 17). (C) 2003 Elsevier Ltd. All rights reserved.